Vyome Holdings, Inc. ("Vyome") (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, on April 21, 2026.

MFWs are non-healing wounds that occur in ~10% of advanced cancer patients (~65K patients in the U.S. alone each year). Patients suffer symptoms such as severe ‘rotten meat' malodor, pain, which negatively impacts quality of life. Patients feel ashamed of the malodor and socially withdraw. There are currently no FDA approved drugs to treat these symptoms of MFW.